Interpreting Key Trials

Renal denervation: What happened, and why?

Mehdi H. Shishehbor, DO, MPH, PhD, Tarek A. Hammad, MD and George Thomas, MD, MPH
Cleveland Clinic Journal of Medicine September 2017, 84 (9) 681-686; DOI: https://doi.org/10.3949/ccjm.84a.14129

Article Information

vol. 84 no. 9 681-686
DOI 
https://doi.org/10.3949/ccjm.84a.14129
PubMed 
28885911
Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online January 1, 2017.
Copyright & Usage 
Copyright © 2017 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Mehdi H. Shishehbor, DO, MPH, PhD⇑
  1. Professor of Medicine, Case Western Reserve University, Cleveland, OH
  2. Co-Chair, Harring Heart and Vascular Institute
  3. Director, Cardiovascular Interventional Center
  4. CoDirector, Vascular Center, University Hospitals of Cleveland, OH
  5. Site Principal Investigator, SYMPLICITY HTN-3 trial
  1. ADDRESS:
    Mehdi H. Shishehbor, DO, MPH, PhD, University Hospitals of Cleveland, 11100 Euclid Avenue, Lakeside, 3rd Floor, Cleveland, OH 44107; shishem{at}gmail.com
  1. Tarek A. Hammad, MD
  1. Department of Medicine, Division of Cardiology, The University of Texas Health Center at San Antonio
  1. George Thomas, MD, MPH
  1. Director, Center for Blood Pressure Disorders, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic
  2. Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  3. Investigator, SYMPLICITY HTN-3 trial

Cited By...

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects